Welcome to our dedicated page for Transmedics Group news (Ticker: TMDX), a resource for investors and traders seeking the latest updates and insights on Transmedics Group stock.
TransMedics Group Inc. (TMDX) is a leader in transforming organ transplantation through its groundbreaking Organ Care System (OCS). This dedicated news hub provides investors, healthcare professionals, and stakeholders with timely updates on clinical advancements, regulatory milestones, and strategic initiatives shaping the future of ex-vivo organ perfusion technology.
Access essential information including earnings reports, FDA clearances, partnership announcements, and clinical trial outcomes. Our curated collection of press releases and verified news articles offers a comprehensive view of TransMedics' progress in improving donor organ viability and transplant success rates.
Key focus areas include innovations in portable organ preservation, expansion of transplant logistics networks, and collaborations with leading medical institutions. Stay informed about developments directly impacting patient outcomes and the company's position within the $50B+ global organ transplant market.
Bookmark this page for streamlined access to critical updates about TMDX's mission to redefine organ transplantation standards through technology-driven solutions.
TransMedics Group, Inc. (NASDAQ: TMDX), a leader in portable organ transplantation technology, announced its Q1 2023 financial results release scheduled for May 1, 2023, after market close. A conference call will follow at 4:30 p.m. ET. TransMedics focuses on improving organ quality and viability assessment, aiming to increase donor organ utilization for patients facing end-stage lung, heart, and liver failure. The company is headquartered in Andover, Massachusetts, and its technologies are crucial in addressing the significant need for better organ transplant solutions.
On February 20, 2023, TransMedics Group (NASDAQ: TMDX) granted non-qualified stock options for 72,774 shares and restricted stock units for 17,092 shares to new employees as part of their inducement to join the company. The options have an exercise price of
TransMedics Group, Inc. (TMDX) reported significant financial growth in its Q4 and full-year 2022 results. Total revenue for Q4 reached $31.4 million, a remarkable 225% increase from Q4 2021, and the full-year revenue totaled $93.5 million, marking a 209% rise compared to 2021. Despite a net loss of $6.7 million for Q4, improved from $12.7 million in Q4 2021, the company continues to invest heavily in its Next Generation Organ Care System (OCS). For 2023, TransMedics anticipates revenue growth to $138 million to $145 million, reflecting an increase of 48% to 55% year-over-year.
TransMedics Group, a leader in organ transplant technology, announced participation in two major investor conferences. The company will engage in a fireside chat at the Cowen 43rd Annual Healthcare Conference on March 6, 2023, at 9:10 a.m. EST, and will present virtually at the Oppenheimer 33rd Annual Healthcare Conference on March 13, 2023, at 12:00 p.m. EST. Both events will feature a live and archived webcast accessible through the TransMedics investor website. TransMedics focuses on innovative solutions to enhance organ transplant therapies for patients facing end-stage organ failure.
FAQ
What is the current stock price of Transmedics Group (TMDX)?
What is the market cap of Transmedics Group (TMDX)?
